Upstream Bio, Inc. (UPB) Financial Statements (2026 and earlier)

Company Profile

Business Address 890 WINTER STREET, SUITE 200
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments341,509470,451
Cash and cash equivalent101,578325,892
Short-term investments239,931144,559
Receivables2,3211,180
Prepaid expense6,2046,125
Other undisclosed current assets1,7631,404
Total current assets:351,797479,160
Noncurrent Assets
Operating lease, right-of-use asset1,2221,783
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization559582
Restricted cash and investments194194
Total noncurrent assets:1,9752,559
TOTAL ASSETS:353,772481,719
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,6757,226
Accounts payable2,7264,041
Accrued liabilities4,9493,185
Other undisclosed current liabilities5,7773,511
Total current liabilities:13,45210,737
Noncurrent Liabilities
Liabilities, other than long-term debt5491,130
Operating lease, liability5491,130
Total noncurrent liabilities:5491,130
Total liabilities:14,00111,867
Equity
Equity, attributable to parent339,771469,852
Common stock5453
Additional paid in capital673,410660,604
Accumulated other comprehensive income (loss)530(25)
Accumulated deficit(334,223)(190,780)
Total equity:339,771469,852
TOTAL LIABILITIES AND EQUITY:353,772481,719

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
Revenues2,8542,370
Cost of revenue
(Cost of Product and Service Sold)
(23,013)(6,580)
Gross profit:(20,159)(4,210)
Operating expenses(163,215)(80,134)
Other undisclosed operating income23,0136,580
Operating loss:(160,361)(77,764)
Nonoperating income16,91814,958
Investment income, nonoperating16,93312,123
Net loss attributable to parent:(143,443)(62,806)
Preferred stock dividends and other adjustments  (13,589)
Net loss available to common stockholders, diluted:(143,443)(76,395)

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
Net loss:(143,443)(62,806)
Comprehensive loss:(143,443)(62,806)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent555(46)
Comprehensive loss, net of tax, attributable to parent:(142,888)(62,852)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: